AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 3,657,353 shares, an increase of 63.9% from the June 15th total of 2,231,389 shares. Based on an average daily volume of 16,762,289 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.2% of the shares of the company are sold short.
A number of hedge funds have recently bought and sold shares of AVEO. NEA Management Company LLC raised its stake in AVEO Pharmaceuticals by 57.9% in the first quarter. NEA Management Company LLC now owns 16,362,694 shares of the biopharmaceutical company’s stock valued at $9,654,000 after buying an additional 6,000,000 shares during the period. Sphera Funds Management LTD. bought a new stake in AVEO Pharmaceuticals during the first quarter valued at approximately $1,711,000. Perceptive Advisors LLC raised its stake in AVEO Pharmaceuticals by 64.3% in the first quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock valued at $3,014,000 after buying an additional 2,000,000 shares during the period. Sabby Management LLC bought a new stake in AVEO Pharmaceuticals during the first quarter valued at approximately $513,000. Finally, UBS Oconnor LLC bought a new stake in AVEO Pharmaceuticals during the first quarter valued at approximately $291,000. 50.96% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have issued reports on AVEO. FBR & Co restated a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Saturday, April 8th. Piper Jaffray Companies set a $2.00 price target on AVEO Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research cut AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 27th. Finally, ValuEngine cut AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
AVEO Pharmaceuticals (NASDAQ AVEO) opened at 2.52 on Friday. The stock’s market capitalization is $278.11 million. AVEO Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $3.19. The stock’s 50 day moving average price is $1.65 and its 200-day moving average price is $0.93.
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of $2.53 million for the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. On average, equities analysts expect that AVEO Pharmaceuticals will post ($0.39) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/07/21/aveo-pharmaceuticals-inc-aveo-short-interest-up-63-9-in-june.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
